世界のKRAS阻害剤市場(~2025):市場機会・臨床試験動向

◆英語タイトル:Global KRAS Inhibitors Market Opportunity and Clinical Trials Outlook 2025
◆商品コード:KUIK21FB004
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2021年1月
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD2,000 ⇒換算¥228,000見積依頼/購入/質問フォーム
Multi UserUSD3,600 ⇒換算¥410,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界のKRAS阻害剤市場について調査・分析を行い、イントロダクション、がんにおけるKRAS阻害剤の役割、作用機序、肺がんにおけるKRAS阻害剤、膵臓がんにおけるKRAS阻害剤、結腸直腸がんにおけるKRAS阻害剤、その他がんにおけるKRAS阻害剤、臨床試験の指標、臨床パイプライン、市場分析、市場動向、将来見通し、競争状況などを掲載しています。
・イントロダクション
・がんにおけるKRAS阻害剤の役割
・作用機序
・肺がんにおけるKRAS阻害剤
・膵臓がんにおけるKRAS阻害剤
・結腸直腸がんにおけるKRAS阻害剤
・その他がんにおけるKRAS阻害剤
・臨床試験の指標
・臨床パイプライン
・市場分析
・市場動向
・将来見通し
・競争状況
【レポートの概要】

“Global KRAS Inhibitors Market Opportunity and Clinical Trials Outlook 2025″ Report Highlights:

KRAS Inhibitors Market Opportunity: > USD 1 Billion by 2025
Initially US To Dominate KRAS Inhibitors Market: >90% Market Share
Number of KRAS Inhibitors In Trials: > 20 Drugs
Highest Phase of Clinical Development: Phase-III Study
Solid Tumors Targeted Drugs Dominating The Clinical Trials
Global KRAS Inhibitors Market Trends and Dynamics
Global KRAS Inhibitors Market Future Opportunity Outlook

The accelerating pace of the cancer cases at global level has led to the arrival of a unique and application-based therapy market, known as KRAS inhibitors. In the past few years, the therapy has been able to show favorable response involving the cell cycle, which is the ultimate target of the cancer cells for continue its proliferation and division in the patients. A cluster of innovative drugs that target KRAS protein has been developed by the researchers and bunch of novel product candidate targeting KRAS protein is currently active in the clinical trials. It can be stated for KRAS inhibitors that it is among the top emerging sectors of the cancer therapeutics market which is due to the splendid research and development pipeline associated with the market. The entire market associated with KRAS inhibitors, in a very short period of time has been able to shift the entire cancer landscape, thus resulting in the standard care of cancer treatment with appropriate opportunities to the patients and the investors.

The drugs developed under the market, inhibits KRAS protein and further the important signaling pathways, ultimately leading to the cell cycle arrest and killing of the cancer cells. Such switching on and off of the cell cycle with the help of hundreds of KRAS inhibitors developed by the researchers is estimated to improve the overall paradigm for efficient targeting, minimal side-effect development, increased effectiveness and efficiency against different types of tumor antigens. The overall increase in the spending for research-based formulas for KRAS inhibitors is also estimated to develop a market that is worth trillions of dollars and decrease the burden that is getting reflected in the cancer therapeutics market with respect to efficient targeting of the cancer cells.

Despite having numerous challenges which were set by the already driven cancer therapies in the market such as chemotherapy or radiation therapy, the novel KRAS inhibitor market has made its impact on the overall running paradigm of cancer therapeutics at global level. The pharmaceutical research sector affiliated with KRAS inhibitor market has weathered down the complex challenges of developing drug candidates with 100% efficacy.
Now-a-days, the KRAS inhibitor market at global level is getting adjoined with novel techniques and technologies that are apparently leading to reinventing the entire cancer market and research-based sector. No doubt, the entire market has led to an opening of novel frontiers that could unravel the complex mechanism of cancer cells and how it could get regulated by controlling the proteins responsible for cell cycle. In addition to this, some of the parameters that are leading to the exponential growth of the market in the past few years include: healthcare benefits associated with the drug candidates and increased awareness about the side-effects of old and traditional cancer therapies such as chemotherapy.

As per the report findings, it can be estimated that the market is completely getting catalyzed by the increased applications of healthcare benefits and variety of disruptive technologies and drug candidates that are available in the market for different types of tumor antigens. In the novel cancer therapeutics market, partly driven by KRAS inhibitor is believed to be overcoming all the challenges that were difficult to crack before the arrival of the KRAS inhibitor therapy.

【レポートの目次】

Introduction to KRAS Inhibitors
1.1 Overview
1.2 Evolution of KRAS Inhibitors

Role of KRAS Inhibitors in Cancer

KRAS Inhibitors – Mode of Action

KRAS Inhibitors For Targeting Lung Cancer
4.1 Impact of KRAS Inhibitors on Lung Cancer
4.2 Ongoing Research and Development
4.2.1 AMG 510 (Sotorasib)
4.2.2 MRTX849 (Adagrasib)
4.2.3 Other Investigational KRAS Inhibitors for Lung Cancer

KRAS Inhibitors in Pancreatic Cancer
5.1 Role of KRAS Inhibitors in Pancreatic Cancer
5.2 Recent Advancement in Pancreatic Cancer Targeting KRAS Inhibitors

KRAS Inhibitors for Colorectal Cancer
6.1 Potential of KRAS Inhibitors Against Colorectal Cancer
6.2 Ongoing Research and Development

KRAS inhibitors For Other Cancers
7.1 Potential of KRAS Inhibitors as Hematological Cancer Therapeutics
7.2 KRAS inhibitors in Prostate Cancer
7.3 KRAS Inhibitors for Gastric Cancer
7.4 KRAS Inhibition in Endometrium Cancer
7.5 Role of KRAS Inhibitors in Brain Cancer

Global KRAS Protein inhibitors Clinical Trials Indicators
8.1 By Phase
8.2 By Country
8.3 By Company
8.4 By Indication
8.5 By Patient Segment

Global KRAS Protein inhibitors Clinical Pipeline By Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III

Global KRAS Inhibitors Market Analysis: Current Scenario

Global KRAS Inhibitors Market Trends
11.1 Revolution Medicines’ KRAS-G12(ON) Inhibitor Shows Prominent Anti-Tumor
Activity
11.2 Boehringer Ingelheim and Mirati Therapeutics Collaborated to Study
Combinational KRAS Inhibitor Therapy
11.3 Merck Signed a Licensing Deal with Taiho and Astex for Developing KRAS
Targeting Therapies
11.4 Strata Collaborated with Mirati Therapeutics for Conducting Trial of MRTX849
11.5 Revolution Medicine Collaborated with Amgen to Evaluate SHP2 and KRAS
Inhibitors Combinational Therapy
11.6 Oncogenuity – New Player in KRAS Inhibitor Development
11.7 Miratis and Novartis Collaborated to Assess KRAS Inhibitor Based Combinational
Therapy

Global KRAS Inhibitors Market Dynamics
12.1 Driving Factors for KRAS Inhibitor Market
12.2 Challenges for KRAS Inhibitors Market

Global KRAS Inhibitors Market Future Opportunity Outlook

Competitive Landscape
14.1 Amgen
14.2 Mirati Therapeutics
14.3 Revolution Medicines
14.4 Boehringer Ingelheim
14.5 Merck
14.6 Moderna
14.7 Silenseed
14.8 Johnson and Johnson
14.9 Eli Lilly
14.10 Oblique Therapeutics
14.11 Cotinga Pharmaceuticals
14.12 Codiak Biosciences
14.13 Gilead



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のKRAS阻害剤市場(~2025):市場機会・臨床試験動向]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆